Results 201 to 210 of about 55,676 (335)

“Nomen Omen: The Myth of God Janus”

open access: yes
JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley   +1 more source

Mechanosensitive Cell‐Laden Shape‐Memory Scaffolds Engineered via Cryogelation

open access: yesSmall Structures, EarlyView.
GelMA‐based shape‐memory scaffolds encapsulating human adipose‐derived stem cells are fabricated via cryogelation, showing rapid recovery and high cell viability. Under cyclic compression, they promoted mechanotransduction gene expression, and composite formulations (collagen/GelMA, dECM/GelMA) retained robust shape‐memory, highlighting their promise ...
JaeYoon Lee   +4 more
wiley   +1 more source

Integrated multi‐omics analysis reveals metabolic reprogramming as a key driver of angiotensin II‐induced vascular remodeling

open access: yesVIEW, EarlyView.
This study investigates the molecular alterations underlying angiotensin II (Ang II)‐induced vascular remodeling in cardiovascular diseases using a multi‐omics approach. Through data exploration and integrated multi‐omics analysis, our findings reveal that Ang II‐driven vascular injury in vascular smooth muscle cells is mediated by metabolic ...
Yiwei Hu   +8 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy